Molecular pharmacology and structure of VPAC receptors for VIP and PACAP

Regulatory Peptides

Volumn 108, Issue 2-3, 2002, Pages 165-173

  Laburthe, M ^a   Couvineau, A ^a  

^a INSERM   (France)

Author keywords

Class II GPCR; G protein coupled receptor (GPCR); PACAP; Receptor chimeras; Site directed mutagenesis; Structural modeling; VIP; VPAC receptors

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LIGAND; NEUROPEPTIDE; RECEPTOR VPAC1; RECEPTOR VPAC2; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

AGONIST; ARTICLE; CHIMERA; HUMAN; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SCIENCE;

EID: 0037107385     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00099-X     Document Type: Article

References (93)

1. Said S.I. Vasoactive intestinal peptide. J. Endocrinol. Investig. 9:1986;191-200.
2. Laburthe M., Couvineau A., Voisin T. Receptors for Peptides of the VIP/PACAP and PYY/NPY/PP. Gastrointest. Endocrinol. 1999;125-157.
3. Gressens P., Hill J.M., Gozes I.et al. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature. 362:1993;155-158.
4. Waschek J.A. Vasoactive intestinal peptide: an important trophic factor and developmental regulator? Dev. Neurosci. 17:1995;1-7.
5. Gozes I., Fridkinb M., Hill J.M.et al. Pharmaceutical VIP: prospects and problems. Curr. Med. Chem. 6:1999;1019-1034.
6. Dickinson T., Fleetwood-Walker S.M. VIP and PACAP: very important in pain? Trends Pharmacol. Sci. 20:1999;324-329.
7. Said S.I. VIP and PACAP in pain and inflammation. Trends Pharmacol. Sci. 21:2000;57.
8. Delgado M., Ganea D. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166:2001;2907-2912.
9. Desbuquois B. The interaction of vasoactive intestinal polypeptide and secretin with liver-cell membranes. Eur. J. Biochem. 46:1974;439-450.
10. Bataille D., Freychet P., Rosselin G. Interactions of glucagon, gut glucagon, vasoactive intestinal polypeptide and secretin with liver and fat cell plasma membranes: binding to specific sites and stimulation of adenylate cyclase. Endocrinology. 95:1974;713-721.
11. Christophe J.P., Conlon T.P., Gardner J.D. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Binding of radioiodinated peptide. J. Biol. Chem. 251:1976;4629-4634.
12. Laburthe M., Prieto J.C., Amiranoff B.et al. Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 2. Characterization and structural requirements of the stimulatory effect of vasoactive intestinal peptide on production of adenosine 3′:5′-monophosphate. Eur. J. Biochem. 96:1979;239-248.
13. Prieto J.C., Laburthe M., Rosselin G. Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 1. Characterization, quantitative aspects and structural requirements of binding sites. Eur. J. Biochem. 96:1979;229-237.
14. Laburthe M., Rousset M., Boissard C.et al. Vasoactive intestinal peptide: a potent stimulator of adenosine 3′:5′-cyclic monophosphate accumulation in gut carcinoma cell lines in culture. Proc. Natl. Acad. Sci. U. S. A. 75:1978;2772-2775.
15. Laburthe M., Kitabgi P., Couvineau A.et al. Peptide receptors and signal transduction in the digestive tractx. Handb. Exp. Pharmacol. 106:1993;133-176.
16. Bataille D., Gespach C., Laburthe M.et al. Porcine peptide having N-terminal histidine and C-terminal isoleucine amide (PHI): vasoactive intestinal peptide (VIP) and secretin-like effects in different tissues from the rat. FEBS Lett. 114:1980;240-242.
17. Amiranoff B., Vauclin-Jacques N., Boige N.et al. Interaction of Gila monster venom with VIP receptors in intestinal epithelium of human. A comparison with rat. FEBS Lett. 164:1983;299-302.
18. Laburthe M., Amiranoff B., Boige N.et al. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin. FEBS Lett. 159:1983;89-92.
19. Laburthe M., Couvineau A., Rouyer-Fessard C.et al. Interaction of PHM, PHI and 24-glutamine PHI with human VIP receptors from colonic epithelium: comparison with rat intestinal receptors. Life Sci. 36:1985;991-995.
20. Laburthe M., Couvineau A., Rouyer-Fessard C. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat. Mol. Pharmacol. 29:1986;23-27.
21. Arimura A., Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front. Neuroendocrinol. 16:1995;53-88.
22. Vaudry D., Gonzalez B.J., Basille M.et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52:2000;269-324.
23. Harmar A.J., Arimura A., Gozes I.et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50:1998;265-270.
24. Laburthe M., Couvineau A., Gaudin P.et al. Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Ann. N.Y. Acad. Sci. 805:1996;94-109.
25. Laburthe M., Breant B., Rouyer-Fessard C. Molecular identification of receptors for vasoactive intestinal peptide in rat intestinal epithelium by covalent cross-linking. Evidence for two classes of binding sites with different structural and functional properties. Eur. J. Biochem. 139:1984;181-187.
26. Robichon A., Marie J.C. Selective photolabeling of high and low affinity binding sites for vasoactive intestinal peptide (VIP): evidence for two classes of covalent VIP-receptor complexes in intestinal cell membranes. Endocrinology. 120:1987;978-985.
27. Couvineau A., Amiranoff B., Laburthe M. Solubilization of the liver vasoactive intestinal peptide receptor. Hydrodynamic characterization and evidence for an association with a functional GTP regulatory protein. J. Biol. Chem. 261:1986;14482-14489.
28. Couvineau A., Voisin T., Guijarro L.et al. Purification of vasoactive intestinal peptide receptor from porcine liver by a newly designed one-step affinity chromatography. J. Biol. Chem. 265:1990;13386-13390.
29. Laburthe M., Couvineau A. Molecular analysis of vasoactive intestinal peptide receptors. A comparison with receptors for VIP-related peptides. Ann. N. Y. Acad. Sci. 527:1988;296-313.
30. Ishihara T., Nakamura S., Kaziro Y.et al. Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO J. 10:1991;1635-1641.
31. Ishihara T., Shigemoto R., Mori K.et al. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron. 8:1992;811-819.
32. Sreedharan S.P., Patel D.R., Huang J.X.et al. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun. 193:1993;546-553.
33. Couvineau A., Rouyer-Fessard C., Darmoul D.et al. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem. Biophys. Res. Commun. 200:1994;769-776.
34. Lutz E.M., Sheward W.J., West K.M.et al. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334:1993;3-8.
35. Svoboda M., Tastenoy M., Van Rampelbergh J.et al. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205:1994;1617-1624.
36. Adamou J.E., Aiyar N., Van Horn S.et al. Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem. Biophys. Res. Commun. 209:1995;385-392.
37. McKnight A.J., Gordon S. The EGF-TM7 family: unusual structures at the leukocyte surface. J. Leukoc. Biol. 63:1998;271-280.
38. Stacey M., Lin H.H., Gordon S.et al. LNB-TM7, a group of seven-transmembrane proteins related to family-B G-protein-coupled receptors. Trends Biochem. Sci. 25:2000;284-289.
39. Ulrich C.D., Holtmann M., Miller L.J. Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology. 114:1998;382-397.
40. Sreedharan S.P., Robichon A., Peterson K.E.et al. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc. Natl. Acad. Sci U.S.A. 88:1991;4986-4990.
41. Nagata S., Ishihara T., Robberecht P.et al. RDC1 may not be VIP receptor. Trends Pharmacol. Sci. 13:1992;102-103.
42. Cook J.S., Wolsing D.H., Lameh J.et al. Characterization of the RDC1 gene which encodes the canine homolog of a proposed human VIP receptor. Expression does not correlate with an increase in VIP binding sites. FEBS Lett. 300:1992;149-152.
43. Usdin T.B., Bonner T.I., Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 135:1994;2662-2680.
44. Couvineau A., Laburthe M. The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium. J. Clin. Endocrinol. Metab. 61:1985;50-55.
45. Fabre C., el Battari A., Karamanos Y.et al. Glycosylation of VIP receptors: a molecular basis for receptor heterogeneity. Peptides. 14:1993;483-489.
46. Gaudin P., Couvineau A., Maoret J.J.et al. Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. Eur. J. Pharmacol. 302:1996;207-214.
47. Couvineau A., Rouyer-Fessard C., Maoret J.J.et al. Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J. Biol. Chem. 271:1996;12795-12800.
48. Xia M., Sreedharan S.P., Bolin D.R.et al. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:1997;629-633.
49. Gourlet P., Vandermeers A., Vertongen P.et al. Development of high affinity selective VIP1 receptor agonists. Peptides. 18:1997;1539-1545.
50. Nicole P., Lins L., Rouyer-Fessard C.et al. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J. Biol. Chem. 275:2000;24003-24012.
51. Gourlet P., De Neef P., Cnudde J.et al. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides. 18:1997;1555-1560.
52. Moreno D., Gourlet P., De Neef P.et al. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides. 21:2000;1543-1549.
53. Tams J.W., Jorgensen R.M., Holm A.et al. Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template. Mol. Pharmacol. 58:2000;1035-1041.
54. Juarranz M.G., Van Rampelbergh J., Gourlet P.et al. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands. Mol. Pharmacol. 56:1999;1280-1287.
55. O'Donnell M., Garippa R.J., Rinaldi N.et al. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. J. Pharmacol. Exp. Ther. 270:1994;1289-1294.
56. Gourlet P., Vertongen P., Vandermeers A.et al. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides. 18:1997;403-408.
57. Calvo J.R., Couvineau A., Guijarro L.et al. Solubilization and hydrodynamic characterization of guanine nucleotide sensitive vasoactive intestinal peptide-receptor complexes from rat intestine. Biochemistry. 28:1989;1667-1672.
58. Couvineau A., Rouyer-Fessard C., Voisin T.et al. Functional and immunological evidence for stable association of solubilized vasoactive-intestinal-peptide receptor and stimulatory guanine-nucleotide-binding protein from rat liver. Eur. J. Biochem. 187:1990;605-609.
59. Kermode J.C., DeLuca A.W., Zilberman A.et al. Evidence for the formation of a functional complex between vasoactive intestinal peptide, its receptor, and Gs in lung membranes. J. Biol. Chem. 267:1992;3382-3388.
60. Shreeve S.M., Sreedharan S.P., Hacker M.P.et al. VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor. Biochem. Biophys. Res. Commun. 272:2000;922-928.
61. Laburthe M., Mangeat P., Marchis-Mouren G.et al. Activation of cyclic AMP-dependent protein kinases by vasoactive intestinal peptide (VIP) in isolated intestinal epithelial cells from rat. Life Sci. 25:1979;1931-1937.
62. Van Rampelbergh J., Poloczek P., Francoys I.et al. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim. Biophys. Acta. 1357:1997;249-255.
63. McCulloch D.A., Lutz E.M., Johnson M.S.et al. Differential activation of phospholipase D by VPAC and PAC1 receptors. Ann. N.Y. Acad. Sci. 921:2000;175-185.
64. McCulloch D.A., Lutz E.M., Johnson M.S.et al. ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant. Mol. Pharmacol. 59:2001;1523-1532.
65. MacKenzie C.J., Lutz E.M., Johnson M.S.et al. Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor. Endocrinology. 142:2001;1209-1217.
66. Luo X., Zeng W., Xu X.et al. Alternate coupling of receptors to Gs and Gi in pancreatic and submandibular gland cells. J. Biol. Chem. 274:1999;17684-17690.
67. Teng B., Murthy K.S., Kuemmerle J.F.et al. Selective expression of vasoactive intestinal peptide (VIP)2/pituitary adenylate cyclase-activating polypeptide (PACAP)3 receptors in rabbit and guinea pig gastric and tenia coli smooth muscle cells. Regul. Pept. 77:1998;127-134.
68. Murthy K.S., Makhlouf G.M. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide-dependent activation of membrane-bound NO synthase in smooth muscle mediated by pertussis toxin-sensitive Gi1-2. J. Biol. Chem. 269:1994;15977-15980.
69. Murthy K.S., Makhlouf G.M. Interaction of cA-kinase and cG-kinase in mediating relaxation of dispersed smooth muscle cells. Am. J. Physiol. 268:1995;C171-C180.
70. Murthy K.S., Makhlouf G.M. Differential regulation of phospholipase A2 (PLA2)-dependent Ca2+ signaling in smooth muscle by. J. Biol. Chem. 273:1998;34519-34526.
71. Gressens P., Marret S., Hill J.M.et al. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100:1997;390-397.
72. Couvineau A., Gaudin P., Maoret J.J.et al. Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem. Biophys. Res. Commun. 206:1995;246-252.
73. Nicole P., Du K., Couvineau A.et al. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. J. Pharmacol. Exp. Ther. 284:1998;744-750.
74. Nicole P., Maoret J.J., Couvineau A.et al. Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding. Biochem. Biophys. Res. Commun. 276:2000;654-659.
75. Gaudin P., Couvineau A., Maoret J.J.et al. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem. Biophys. Res. Commun. 211:1995;901-908.
76. Couvineau A., Fabre C., Gaudin P.et al. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry. 35:1996;1745-1752.
77. Lins L., Couvineau A., Rouyer-Fessard C.et al. The human VPAC1 receptor: three-dimensional model and mutagenesis of the N-terminal domain. J. Biol. Chem. 276:2001;10153-10160.
78. Du K., Nicole P., Couvineau A.et al. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. Biochem. Biophys. Res. Commun. 230:1997;289-292.
79. Knudsen S.M., Tams J.W., Wulff B.S.et al. A disulfide bond between conserved cysteines in the extracellular loops of the human VIP receptor is required for binding and activation. FEBS Lett. 412:1997;141-143.
80. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21:2000;90-113.
81. Solano R.M., Langer I., Perret J.et al. Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J. Biol. Chem. 276:2001;1084-1088.
82. Gourlet P., Vilardaga J.P., De Neef P.et al. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides. 17:1996;825-829.
83. Jin L., Briggs S.L., Chandrasekhar S.et al. Crystal structure of human parathyroid hormone 1-34 at 0.9 - A resolution. J. Biol. Chem. 275:2000;27238-27244.
84. Holtmann M.H., Hadac E.M., Miller L.J. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J. Biol. Chem. 270:1995;14394-14398.
85. Park C.G., Ganguli S.C., Pinon D.I.et al. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation. J. Pharmacol. Exp. Ther. 295:2000;682-688.
86. Vilardaga J.P., De Neef P., Di Paolo E.et al. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochem. Biophys. Res. Commun. 211:1995;885-891.
87. Du K., Nicole P., Couvineau A.et al. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP. Ann. N.Y. Acad. Sci. 865:1998;386-389.
88. Olde B., Sabirsh A., Owman C. Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor. J. Mol. Neurosci. 11:1998;127-134.
89. Hashimoto H., Ogawa N., Hagihara N.et al. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol. Pharmacol. 52:1997;128-135.
90. Lutz E.M., MacKenzie C.J., Johnson M.et al. Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors. Br. J. Pharmacol. 128:1999;934-940.
91. Juarranz M.G., Van Rampelbergh J., Gourlet P.et al. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation. Eur. J. Biochem. 265:1999;449-456.
92. Tibaduiza E.C., Chen C., Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J. Biol. Chem. 276:2001;37787-37793.
93. Gourlet P., Vandermeers-Piret M.C., Rathe J.et al. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes. Eur. J. Pharmacol. 348:1998;95-99.